Bridging Knowledge Gaps in the Diagnosis and Management of Neuropsychiatric Sequelae of COVID-19 | Coronavirus (COVID-19) | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Bridging Knowledge Gaps in the Diagnosis and Management of Neuropsychiatric Sequelae of COVID-19

To identify the key insights or developments described in this article
1 Credit CME
Abstract

Importance  Neuropsychiatric symptoms have been reported as a prominent feature of postacute sequelae of COVID-19 (PASC), with common symptoms that include cognitive impairment, sleep difficulties, depression, posttraumatic stress, and substance use disorders. A primary challenge of parsing PASC epidemiology and pathophysiology is the lack of a standard definition of the syndrome, and little is known regarding mechanisms of neuropsychiatric PASC.

Observations  Rates of symptom prevalence vary, but at least 1 PASC neuropsychiatric symptom has been reported in as many as 90% of patients 6 months after COVID-19 hospitalization and in approximately 25% of nonhospitalized adults with COVID-19. Mechanisms of neuropsychiatric sequelae of COVID-19 are still being elucidated. They may include static brain injury accrued during acute COVID-19, neurodegeneration triggered by secondary effects of acute COVID-19, autoimmune mechanisms with chronic inflammation, viral persistence in tissue reservoirs, or reactivation of other latent viruses. Despite rapidly emerging data, many gaps in knowledge persist related to the variable definitions of PASC, lack of standardized phenotyping or biomarkers, variability in virus genotypes, ascertainment biases, and limited accounting for social determinants of health and pandemic-related stressors.

Conclusions and Relevance  Growing data support a high prevalence of PASC neuropsychiatric symptoms, but the current literature is heterogeneous with variable assessments of critical epidemiological factors. By enrolling large patient samples and conducting state-of-the-art assessments, the Researching COVID to Enhance Recovery (RECOVER), a multicenter research initiative funded by the National Institutes of Health, will help clarify PASC epidemiology, pathophysiology, and mechanisms of injury, as well as identify targets for therapeutic intervention.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: May 2, 2022.

Published Online: June 29, 2022. doi:10.1001/jamapsychiatry.2022.1616

Corresponding Author: Naomi M. Simon, MD, MSc, Department of Psychiatry, NYU Grossman School of Medicine, One Park Avenue, 8th Floor, New York, NY 10016 (naomi.simon@nyulangone.org).

Author Contributions: Drs Frontera and Simon had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Both authors.

Acquisition, analysis, or interpretation of data: Both authors.

Drafting of the manuscript: Both authors.

Critical revision of the manuscript for important intellectual content: Both authors.

Administrative, technical, or material support: Frontera.

Conflict of Interest Disclosures: Dr Frontera reported grants from the National Institutes of Health (NIH), consulting support from FirstKind and Braincool, publishing fees from Thieme, and speaking fees from Physician Education Resource (PER) outside the submitted work. Dr Simon reported grants from the NIH during the conduct of the study; grants from the NIH, Patient-Centered Outcomes Research Institute, Department of Defense, American Foundation for Suicide Prevention, Cohen Veterans Network, and Vanda Pharmaceuticals; consulting fees from Vanda Pharmaceuticals, Bionomics Limited, BehavR LLC, Praxis Therapeutics, Cerevel, Genomind, and Engrail Therapeutics; spousal equity in G1 Therapeutics and Zentalis; and royalties or fees from APA Publishing, Wolters Kluwer (UpToDate), and Wiley (Deputy Editor, Depression and Anxiety) outside the submitted work. No other disclosures were reported.

Funding/Support: Both authors receive funding as co-investigators/faculty at the NYU Grossman School of Medicine for the RECOVER initiative (OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core). Dr Frontera receives funding for the following COVID-19–related grants from these NIH institutes: National Institute of Neurological Disorders and Stroke (3U24NS11384401S1), National Heart, Lung, and Blood Institute (1OT2HL161847-01), and National Institute on Aging (3P30AG066512-01).

Role of the Funder/Sponsor: The funding organization had no role in the preparation, review, or approval of the manuscript or decision to submit the manuscript for publication.

Additional Information: There was no original data collection or analyses for this Special Communication.

References
1.
National Institutes of Health. Researching COVID to Enhance Recovery initiative (RECOVER). Accessed May 25, 2022. https://recovercovid.org
2.
Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. Updated May 5, 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
3.
World Health Organization. A clinical case definition of post COVID-19 condition by Delphi consensus. Published October 6, 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
4.
Venkatesan  P .  NICE guideline on long COVID.   Lancet Respir Med. 2021;9(2):129. doi:10.1016/S2213-2600(21)00031-XPubMedGoogle ScholarCrossref
5.
Oran  DP , Topol  EJ .  The proportion of SARS-CoV-2 infections that are asymptomatic.   Ann Intern Med. 2021;174(9):1344-1345. doi:10.7326/L21-0491PubMedGoogle ScholarCrossref
6.
Frontera  JA , Sabadia  S , Lalchan  R ,  et al.  A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City.   Neurology. 2021;96(4):e575-e586. doi:10.1212/WNL.0000000000010979PubMedGoogle ScholarCrossref
7.
Misra  S , Kolappa  K , Prasad  M ,  et al.  Frequency of neurologic manifestations in COVID-19: a systematic review and meta-analysis.   Neurology. 2021;97(23):e2269-e2281. doi:10.1212/WNL.0000000000012930PubMedGoogle ScholarCrossref
8.
Wang  L , Shen  Y , Li  M ,  et al.  Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis.   J Neurol. 2020;267(10):2777-2789. doi:10.1007/s00415-020-09974-2PubMedGoogle ScholarCrossref
9.
Deng  J , Zhou  F , Hou  W ,  et al.  The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis.   Ann N Y Acad Sci. 2021;1486(1):90-111. doi:10.1111/nyas.14506PubMedGoogle ScholarCrossref
10.
García-Azorín  D , Sierra  Á , Trigo  J ,  et al.  Frequency and phenotype of headache in covid-19: a study of 2194 patients.   Sci Rep. 2021;11(1):14674. doi:10.1038/s41598-021-94220-6PubMedGoogle ScholarCrossref
11.
Krishnamoorthy  Y , Nagarajan  R , Saya  GK , Menon  V .  Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: a systematic review and meta-analysis.   Psychiatry Res. 2020;293:113382. doi:10.1016/j.psychres.2020.113382PubMedGoogle ScholarCrossref
12.
Frontera  JA , Lewis  A , Melmed  K ,  et al.  Prevalence and predictors of prolonged cognitive and psychological symptoms following COVID-19 in the United States.   Front Aging Neurosci. 2021;13:690383. doi:10.3389/fnagi.2021.690383PubMedGoogle ScholarCrossref
13.
Groff  D , Sun  A , Ssentongo  AE ,  et al.  Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review.   JAMA Netw Open. 2021;4(10):e2128568. doi:10.1001/jamanetworkopen.2021.28568PubMedGoogle ScholarCrossref
14.
Frontera  JA , Yang  D , Lewis  A ,  et al.  A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications.   J Neurol Sci. 2021;426:117486. doi:10.1016/j.jns.2021.117486PubMedGoogle ScholarCrossref
15.
Taquet  M , Dercon  Q , Luciano  S , Geddes  JR , Husain  M , Harrison  PJ .  Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19.   PLoS Med. 2021;18(9):e1003773. doi:10.1371/journal.pmed.1003773PubMedGoogle ScholarCrossref
16.
Taquet  M , Geddes  JR , Husain  M , Luciano  S , Harrison  PJ .  6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records.   Lancet Psychiatry. 2021;8(5):416-427. doi:10.1016/S2215-0366(21)00084-5PubMedGoogle ScholarCrossref
17.
Ceban  F , Ling  S , Lui  LMW ,  et al.  Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis.   Brain Behav Immun. 2022;101:93-135. doi:10.1016/j.bbi.2021.12.020PubMedGoogle ScholarCrossref
18.
Pun  BT , Badenes  R , Heras La Calle  G ,  et al; COVID-19 Intensive Care International Study Group.  Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study.   Lancet Respir Med. 2021;9(3):239-250. doi:10.1016/S2213-2600(20)30552-XPubMedGoogle ScholarCrossref
19.
Becker  JH , Lin  JJ , Doernberg  M ,  et al.  Assessment of cognitive function in patients after COVID-19 infection.   JAMA Netw Open. 2021;4(10):e2130645. doi:10.1001/jamanetworkopen.2021.30645PubMedGoogle ScholarCrossref
20.
Del Brutto  OH , Wu  S , Mera  RM , Costa  AF , Recalde  BY , Issa  NP .  Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: a longitudinal prospective study nested to a population cohort.   Eur J Neurol. 2021;28(10):3245-3253. doi:10.1111/ene.14775PubMedGoogle ScholarCrossref
21.
Baldini  T , Asioli  GM , Romoli  M ,  et al.  Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis.   Eur J Neurol. 2021;28(10):3478-3490. doi:10.1111/ene.14727PubMedGoogle ScholarCrossref
22.
Tamaki  A , Cabrera  CI , Li  S ,  et al.  Incidence of Bell palsy in patients with COVID-19.   JAMA Otolaryngol Head Neck Surg. 2021;147(8):767-768. doi:10.1001/jamaoto.2021.1266PubMedGoogle ScholarCrossref
23.
Taquet  M , Luciano  S , Geddes  JR , Harrison  PJ .  Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA.   Lancet Psychiatry. 2021;8(2):130-140. doi:10.1016/S2215-0366(20)30462-4PubMedGoogle ScholarCrossref
24.
Schou  TM , Joca  S , Wegener  G , Bay-Richter  C .  Psychiatric and neuropsychiatric sequelae of COVID-19: a systematic review.   Brain Behav Immun. 2021;97:328-348. doi:10.1016/j.bbi.2021.07.018PubMedGoogle ScholarCrossref
25.
Al-Aly  Z , Xie  Y , Bowe  B .  High-dimensional characterization of post-acute sequelae of COVID-19.   Nature. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9PubMedGoogle ScholarCrossref
26.
Bourmistrova  NW , Solomon  T , Braude  P , Strawbridge  R , Carter  B .  Long-term effects of COVID-19 on mental health: a systematic review.   J Affect Disord. 2022;299:118-125. doi:10.1016/j.jad.2021.11.031PubMedGoogle ScholarCrossref
27.
Mazza  MG , Palladini  M , De Lorenzo  R ,  et al; COVID-19 BioB Outpatient Clinic Study group.  Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up.   Brain Behav Immun. 2021;94:138-147. doi:10.1016/j.bbi.2021.02.021PubMedGoogle ScholarCrossref
28.
Vai  B , Mazza  MG , Delli Colli  C ,  et al.  Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis.   Lancet Psychiatry. 2021;8(9):797-812. doi:10.1016/S2215-0366(21)00232-7PubMedGoogle ScholarCrossref
29.
Su  Y , Yuan  D , Chen  DG ,  et al.  Multiple early factors anticipate post-acute COVID-19 sequelae.   Cell. 2022;185(5):881-895.e20. doi:10.1016/j.cell.2022.01.014PubMedGoogle ScholarCrossref
30.
Xiong  Q , Xu  M , Li  J ,  et al.  Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study.   Clin Microbiol Infect. 2021;27(1):89-95. doi:10.1016/j.cmi.2020.09.023PubMedGoogle ScholarCrossref
31.
Hassett  CE , Frontera  JA .  Neurologic aspects of coronavirus disease of 2019 infection.   Curr Opin Infect Dis. 2021;34(3):217-227. doi:10.1097/QCO.0000000000000731PubMedGoogle ScholarCrossref
32.
Pons  S , Fodil  S , Azoulay  E , Zafrani  L .  The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection.   Crit Care. 2020;24(1):353. doi:10.1186/s13054-020-03062-7PubMedGoogle ScholarCrossref
33.
Lee  MH , Perl  DP , Nair  G ,  et al.  Microvascular injury in the brains of patients with COVID-19.   N Engl J Med. 2021;384(5):481-483. doi:10.1056/NEJMc2033369PubMedGoogle ScholarCrossref
34.
Thakur  KT , Miller  EH , Glendinning  MD ,  et al.  COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital.   Brain. 2021;144(9):2696-2708. doi:10.1093/brain/awab148PubMedGoogle ScholarCrossref
35.
Frontera  JA , Boutajangout  A , Masurkar  AV ,  et al.  Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer’s dementia.   Alzheimers Dement. 2022;18(5):899-910. doi:10.1002/alz.12556PubMedGoogle ScholarCrossref
36.
Meinhardt  J , Radke  J , Dittmayer  C ,  et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19.   Nat Neurosci. 2021;24(2):168-175. doi:10.1038/s41593-020-00758-5PubMedGoogle ScholarCrossref
37.
Gupta  A , Bansal  M .  RNA-mediated translation regulation in viral genomes: computational advances in the recognition of sequences and structures.   Brief Bioinform. 2020;21(4):1151-1163. doi:10.1093/bib/bbz054PubMedGoogle ScholarCrossref
38.
Solomon  IH , Normandin  E , Bhattacharyya  S ,  et al.  Neuropathological features of covid-19.   N Engl J Med. 2020;383(10):989-992. doi:10.1056/NEJMc2019373PubMedGoogle ScholarCrossref
39.
Pandharipande  PP , Girard  TD , Jackson  JC ,  et al; BRAIN-ICU Study Investigators.  Long-term cognitive impairment after critical illness.   N Engl J Med. 2013;369(14):1306-1316. doi:10.1056/NEJMoa1301372PubMedGoogle ScholarCrossref
40.
Shi  J , Yang  SH , Stubley  L , Day  AL , Simpkins  JW .  Hypoperfusion induces overexpression of beta-amyloid precursor protein mRNA in a focal ischemic rodent model.   Brain Res. 2000;853(1):1-4. doi:10.1016/S0006-8993(99)02113-7PubMedGoogle ScholarCrossref
41.
Ismail  R , Parbo  P , Madsen  LS ,  et al.  The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study.   J Neuroinflammation. 2020;17(1):151. doi:10.1186/s12974-020-01820-6PubMedGoogle ScholarCrossref
42.
Ferini-Strambi  L , Salsone  M .  COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?   J Neurol. 2021;268(2):409-419. doi:10.1007/s00415-020-10070-8PubMedGoogle ScholarCrossref
43.
Song  E , Bartley  CM , Chow  RD ,  et al.  Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms.   Cell Rep Med. 2021;2(5):100288. doi:10.1016/j.xcrm.2021.100288PubMedGoogle ScholarCrossref
44.
Sotzny  F , Blanco  J , Capelli  E ,  et al; European Network on ME/CFS (EUROMENE).  Myalgic encephalomyelitis/chronic fatigue syndrome: evidence for an autoimmune disease.   Autoimmun Rev. 2018;17(6):601-609. doi:10.1016/j.autrev.2018.01.009PubMedGoogle ScholarCrossref
45.
Estiri  H , Strasser  ZH , Brat  GA , Semenov  YR , Patel  CJ , Murphy  SN ; Consortium for Characterization of COVID-19 by EHR (4CE).  Evolving phenotypes of non-hospitalized patients that indicate long COVID.   BMC Med. 2021;19(1):249. doi:10.1186/s12916-021-02115-0PubMedGoogle ScholarCrossref
46.
Aydillo  T , Gonzalez-Reiche  AS , Aslam  S ,  et al.  Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer.   N Engl J Med. 2020;383(26):2586-2588. doi:10.1056/NEJMc2031670PubMedGoogle ScholarCrossref
47.
Mehandru  S , Merad  M .  Pathological sequelae of long-haul COVID.   Nat Immunol. 2022;23(2):194-202. doi:10.1038/s41590-021-01104-yPubMedGoogle ScholarCrossref
48.
Kappelmann  N , Dantzer  R , Khandaker  GM .  Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19.   Psychoneuroendocrinology. 2021;131:105295. doi:10.1016/j.psyneuen.2021.105295PubMedGoogle ScholarCrossref
49.
Jansen van Vuren  E , Steyn  SF , Brink  CB , Möller  M , Viljoen  FP , Harvey  BH .  The neuropsychiatric manifestations of COVID-19: interactions with psychiatric illness and pharmacological treatment.   Biomed Pharmacother. 2021;135:111200. doi:10.1016/j.biopha.2020.111200PubMedGoogle ScholarCrossref
50.
Hoertel  N .  Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19?   JAMA Netw Open. 2021;4(11):e2136510-e2136510. doi:10.1001/jamanetworkopen.2021.36510PubMedGoogle ScholarCrossref
51.
Valdes  E , Fuchs  B , Morrison  C ,  et al.  Demographic and social determinants of cognitive dysfunction following hospitalization for COVID-19.   J Neurol Sci. 2022;120146:120146. doi:10.1016/j.jns.2022.120146PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close